This inventor holds 2 USPTO granted patents. Top assignee: Ligand Pharmaceuticals, Inc.. Active years: 1996-2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1996-2001
Certainly! Here is the article about inventor Elizabeth A. Allegretto:
Title: Innovator Spotlight - Elizabeth A. Allegretto: Pioneering Non-Secosteroidal Compounds in La Jolla, CA
Introduction:
Elizabeth A. Allegretto is a distinguished inventor based in La Jolla, California, with a penchant for groundbreaking pharmaceutical innovations. With a focus on enhancing drug effectiveness while minimizing side effects, Allegretto's work has garnered attention in the field of medical research.
Latest Patents:
1. Vitamin D3 Mimics: One of Allegretto's recent patents delves into non-secosteroidal compounds that interact with the vitamin D receptor (VDR). These compounds offer similar benefits to 1,25(OH)2D3 but with reduced calcium mobilization effects. They hold promise in treating conditions sensitive to vitamin D and exhibit potential in addressing calcium regulatory, immune responsive, hyperproliferative, and neurodegenerative disorders.
2. Detection of Retinoid X Receptor Subtype Gamma Proteins: Allegretto's innovative peptides derived from RXRX, coupled with specific antibodies, enable the detection of RXRX subtypes in their functional state. This patent outlines methods for immunological assays utilizing these antibodies alongside retinoid receptor ligands for precise detection and measurement of RXR and RAR subtypes.
Career Highlights:
Elizabeth A. Allegretto is a valued member of Ligand Pharmaceuticals, Inc., a pharmaceutical company at the forefront of drug discovery and development. Her work exemplifies Ligand's commitment to pioneering pharmaceutical solutions that cater to diverse medical needs.
Collaborations:
Allegretto collaborates closely with esteemed colleagues at Ligand Pharmaceuticals, Inc., including Marcus F. Boehm and Alex M. Nadzan. Their shared expertise and dedication contribute significantly to the innovative projects undertaken at the company.
Conclusion:
In summary, Elizabeth A. Allegretto's inventive spirit, coupled with her contributions to pharmaceutical research at Ligand Pharmaceuticals, Inc., underscores her role as a trailblazer in the development of novel drug compounds. Her patents offer a glimpse into the future of pharmacological advancements aimed at enhancing patient care and treatment outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile